Celator stock soars after leukemia treatment shows survival benefit

(Reuters) - Celator Pharmaceuticals Inc on Monday said its Vyxeos treatment helped older high-risk patients with a deadly form of leukemia live longer than those who received the standard of care regimen in a late stage clinical trial, sending its stock price soaring.

http://ift.tt/1S0tA2J

from Reuters: Health News
via animenewspro